Ceclazepide

Ceclazepide (TR2-A), a CCK2R antagonist, is an orally active Mycobacterium abscessus inhibitor. Ceclazepide inhibits acid secretion in rats. Ceclazepide effectively suppresses the growth of M. abscessus wild-type strain and multiple subspecies. Ceclazepide inhibits M. abscessus growth within macrophages without causing harm[1][2].

Product Specifications

CAS Number

[1801749-44-9]

Product Name Alternative

TR2-A

UNSPSC

12352005

Target

Bacterial; Cholecystokinin Receptor

Related Pathways

Anti-infection; GPCR/G Protein; Neuronal Signaling

Field of Research

Infection; Cardiovascular Disease

Smiles

CC(OCC(C)(C)C(CN1C2=CC=CC=C2C(C3=CC=CC=N3)=N[C@H](C1=O)NC(NC4=CC(NC)=CC=C4)=O)=O)=O

Molecular Formula

C30H32N6O5

Molecular Weight

556.61

References & Citations

[1]K.L. Therese, et al. Ceclazepide as novel Mycobacterium abscessus inhibitor. bioRxiv. April 03, 2024.|[2]Chen D, et al. Neuroendocrine mechanism of gastric acid secretion: Historical perspectives and recent developments in physiology and pharmacology. J Neuroendocrinol. 2023 Nov;35 (11) :e13305.